Last update 11 Jul 2024

Nedosiran

Overview

Basic Info

Drug Type
Small interfering RNA
Synonyms
DCR-PHSS, DCR-PHXC, Nedosiran sodium
+ [2]
Mechanism
ASGR1 inhibitors(Asialoglycoprotein receptor 1 inhibitors), L-lactate dehydrogenase inhibitors(L-lactate dehydrogenase inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Primary Hyperoxaluria Type 1
US
29 Sep 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Primary Hyperoxaluria Type 2Phase 3
US
09 Jul 2019
Primary Hyperoxaluria Type 2Phase 3
JP
09 Jul 2019
Primary Hyperoxaluria Type 2Phase 3
AU
09 Jul 2019
Primary Hyperoxaluria Type 2Phase 3
CA
09 Jul 2019
Primary Hyperoxaluria Type 2Phase 3
FR
09 Jul 2019
Primary Hyperoxaluria Type 2Phase 3
DE
09 Jul 2019
Primary Hyperoxaluria Type 2Phase 3
IT
09 Jul 2019
Primary Hyperoxaluria Type 2Phase 3
LB
09 Jul 2019
Primary Hyperoxaluria Type 2Phase 3
NL
09 Jul 2019
Primary Hyperoxaluria Type 2Phase 3
NO
09 Jul 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
35
fklpdvkiux(fcxpaeyshz) = odtynnesep oxdzhgmquv (skwfvebsii, tfjolzsfry - jptbsthpdn)
-
22 May 2024
Phase 2
35
RIVFLOZA
yevjhmbomj(xmojwomgvq) = egjlomjeai owedagqett (hucudikimz, -5025 to -1947)
Positive
29 Sep 2023
Placebo
yevjhmbomj(xmojwomgvq) = bxdkgsnbsc owedagqett (hucudikimz, 781 - 3761)
Phase 3
-
aijdfqzeos(sfvvacvqzz) = There were no drug-related SAEs or study discontinuations, or deaths wybcdpohve (ftvejphwbu )
Positive
03 Nov 2022
Placebo
Not Applicable
2
urhdvjacek(tpoysdkzzj) = ckotlitdhx ethuxqdpjq (jtfhubnpto )
Positive
27 Oct 2021
Phase 1
6
xgzxrfwuqr(ariymezfnc) = all AEs were mild and unrelated,cAE was back pain,no SAE efzhjznfsz (akmaniqhmc )
Positive
19 Oct 2021
Placebo
Phase 1
43
(Group A;healthy participants)
uzmfmszlqx(myaoqfweye) = srtnzrpyjw jwmnaeexjs (icktehkwuc )
Positive
02 Sep 2021
(Group B;patients with PH1 or PH2)
uzmfmszlqx(myaoqfweye) = rctifujlai jwmnaeexjs (icktehkwuc )
Not Applicable
-
nmufrxaqyn(chodzcdevp) = vbgrxnpeno fbtlrdnsum (fwuysidlly )
-
01 Sep 2021
Phase 3
16
yrccduxjqs(xwnjzfjqxq) = monkdxqfkh idvzyunybd (rsvjomeehe )
Positive
22 Oct 2020
Phase 3
Primary Hyperoxaluria Type 2
genetically confirmed
16
qzjvazxlox(zqfphlkgvo) = Treatment-emergent adverse events (AEs) were observed in 11 participants. Seven participants experienced 33 AEs considered related to study drug: administration-site events (18), blood chemistry findings (6), pain (2), dysuria (1), nasal congestion (1), edema (1), and erectile dysfunction (1). Three AEs were uncoded at this time. None of the participants experienced injection-site reactions (defined as occurring 4 hr or more after injection). All drug-related AEs were mild. There were no drug-related serious AEs. kzfcoqsqzb (quhaziarpw )
Positive
19 Oct 2020
Phase 1
-
kxlhyysvpp(yhphejyhjb) = acgfaruvxq ujiuvtygwu (rsltpqhiya )
Positive
05 Nov 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free